Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Development and use of FRAX in osteoporosis.

Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F.

Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13. doi: 10.1007/s00198-010-1253-y. Epub 2010 May 13. Review.

PMID:
20464374
2.

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group.

Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28. Erratum in: Osteoporos Int. 2009 Mar;20(3):499-502.

PMID:
18751937
3.

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.

Harvey NC, Kanis JA, Odén A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, McCloskey EV.

Osteoporos Int. 2015 Sep;26(9):2347-53. doi: 10.1007/s00198-015-3129-7. Epub 2015 Jun 20.

4.

Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.

Adler RA, Hastings FW, Petkov VI.

Osteoporos Int. 2010 Apr;21(4):647-53. doi: 10.1007/s00198-009-0984-0. Epub 2009 Jun 17.

PMID:
19533207
5.

[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].

Johansson H, Kanis JA, Ljunggren O, Ström O, Svensson O, Mellström D.

Lakartidningen. 2011 Feb 16-22;108(7):336-9. Review. Swedish. No abstract available.

PMID:
21539116
6.

Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data.

Bastos-Silva Y, Aguiar LB, Pinto-Neto AM, Baccaro LF, Costa-Paiva L.

Arch Osteoporos. 2016;11:16. doi: 10.1007/s11657-015-0255-y. Epub 2016 Apr 11.

PMID:
27067597
7.

[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].

Naranjo A, Ojeda-Bruno S, Francisco-Hernández F, Erausquin C, Rúa-Figueroa I, Rodríguez-Lozano C.

Med Clin (Barc). 2011 Mar 19;136(7):290-2. doi: 10.1016/j.medcli.2010.06.028. Epub 2010 Dec 24. Spanish.

PMID:
21185575
8.

FRAX updates 2016.

McCloskey EV, Harvey NC, Johansson H, Kanis JA.

Curr Opin Rheumatol. 2016 Jul;28(4):433-41. doi: 10.1097/BOR.0000000000000304. Review.

PMID:
27163858
9.

Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women.

Chao AS, Chen FP, Lin YC, Huang TS, Fan CM, Yu YW.

Taiwan J Obstet Gynecol. 2015 Dec;54(6):722-5. doi: 10.1016/j.tjog.2015.10.005.

10.

The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice.

Watts NB.

J Womens Health (Larchmt). 2011 Apr;20(4):525-31. doi: 10.1089/jwh.2010.2294. Epub 2011 Mar 25.

PMID:
21438699
11.

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.

Osteoporos Int. 2015 Nov;26(11):2677-84. doi: 10.1007/s00198-015-3173-3. Epub 2015 Jun 20.

12.

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.

McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA.

J Bone Miner Res. 2012 Jul;27(7):1480-6. doi: 10.1002/jbmr.1606.

13.

Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.

Silverman SL, Komm BS, Mirkin S.

Maturitas. 2014 Nov;79(3):241-7. doi: 10.1016/j.maturitas.2014.07.007. Epub 2014 Jul 16. Review.

PMID:
25124532
14.
15.

A comparison of case-finding strategies in the UK for the management of hip fractures.

Johansson H, Kanis JA, Oden A, Compston J, McCloskey E.

Osteoporos Int. 2012 Mar;23(3):907-15. doi: 10.1007/s00198-011-1864-y. Epub 2012 Jan 11.

PMID:
22234810
16.

Magnitude of fragility fracture risk in the very old--are we meeting their needs? The Newcastle 85+ Study.

Duncan R, Francis RM, Jagger C, Kingston A, McCloskey E, Collerton J, Robinson L, Kirkwood TB, Birrell F.

Osteoporos Int. 2015 Jan;26(1):123-30. doi: 10.1007/s00198-014-2837-8. Epub 2014 Sep 16.

PMID:
25224291
17.

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Kanis JA, Johansson H, Oden A, McCloskey EV.

Osteoporos Int. 2011 Aug;22(8):2347-55. doi: 10.1007/s00198-010-1474-0. Epub 2011 Feb 2. Erratum in: Osteoporos Int. 2011 Aug;22(8):2357-8.

PMID:
21287148
18.

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns.

Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd.

Osteoporos Int. 2010 Jan;21(1):41-52. doi: 10.1007/s00198-009-1034-7. Epub 2009 Aug 25.

PMID:
19705046
19.

FRAX and fracture prediction without bone mineral density.

Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD, McCloskey EV.

Climacteric. 2015;18 Suppl 2:2-9. doi: 10.3109/13697137.2015.1092342. Epub 2015 Oct 21. Review.

PMID:
26489076
20.

High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice.

Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA; Manitoba Bone Density Program.

Osteoporos Int. 2012 Jan;23(1):391-7. doi: 10.1007/s00198-011-1592-3. Epub 2011 Mar 2.

PMID:
21365460

Supplemental Content

Support Center